Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled Trials
Open Access
- 1 January 2012
- journal article
- Published by Hindawi Limited in Anemia
- Vol. 2012, 1-9
- https://doi.org/10.1155/2012/172104
Abstract
Background. Iron deficiency anemia (IDA) is a common hematological complication with potentially serious clinical consequences that may require intravenous iron therapy. Ferric carboxymaltose (FCM) is a stable, nondextran iron formulation administered intravenously in large single doses to treat IDA.Objective. Two open-label, randomized, placebo-controlled trials evaluated safety of multiple or single 750 mg FCM doses compared to standard medical care (SMC) in IDA patients. Secondary endpoints were improvements in hemoglobin and iron indices.Design and Patients. Adults with hemoglobin ≤12 g/dL, ferritin ≤100 or ≤300 ng/mL with transferrin saturation ≤30% were randomized to receive single () or weekly () FCM or SMC (and).Results. Significantly greater () increases in hemoglobin and iron indices occurred in FCM groups versus SMC. In the multidose study, up to two infusions of FCM were needed to reach target iron levels versus 3–5 of intravenous iron comparators. FCM and SMC groups had similar incidences and types of adverse events and serious adverse events. Transient hypophosphatemia not associated with adverse events or clinical sequelae occurred in the FCM groups.Conclusion. Intravenous FCM is safe, well tolerated, and associated with improvements in hemoglobin and iron indices comparable to SMC when administered in single doses of up to 750 mg at a rate of 100 mg/min. Fewer FCM infusions were required to reach target iron levels compared to other intravenous iron preparations.
Keywords
Funding Information
- Luitpold Pharmaceuticals, Inc.
This publication has 30 references indexed in Scilit:
- Severe Hypophosphatemia After Intravenous Administration of Iron Carboxymaltose in a Stable Renal Transplant RecipientTransplantation, 2010
- The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a reviewArzneimittelforschung, 2010
- Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorderArzneimittelforschung, 2010
- THE EFFICACY OF A SINGLE DOSE OF INTRAVENOUS FERRIC CARBOXYMALTOSE (FERINJECT®) ON ANAEMIA IN A PRE-DIALYSIS POPULATION OF CHRONIC KIDNEY DISEASE PATIENTSJournal of Renal Care, 2009
- A Novel Intravenous Iron Formulation for Treatment of Anemia in Inflammatory Bowel Disease: The Ferric Carboxymaltose (FERINJECT®) Randomized Controlled TrialThe American Journal of Gastroenterology, 2008
- Common Misconceptions in the Diagnosis and Management of Anemia in Inflammatory Bowel DiseaseThe American Journal of Gastroenterology, 2008
- II. Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease in AdultsAmerican Journal of Kidney Diseases, 2006
- Iron deficiency: A concise reviewAmerican Journal of Hematology, 2005
- Commentary on “Evidence That Iron Deficiency Anemia Causes Reduced Work Capacity”Journal of Nutrition, 2001
- Prediction of Coronary Heart Disease Using Risk Factor CategoriesCirculation, 1998